R328
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 49
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.540
- INTERFERON_ALPHA_RESPONSE+0.490
- E2F_TARGETS+0.420
- INTERFERON_GAMMA_RESPONSE+0.420
- G2M_CHECKPOINT+0.380
- MTORC1_SIGNALING+0.360
- MYC_TARGETS_V1+0.360
- FATTY_ACID_METABOLISM+0.350
- MITOTIC_SPINDLE+0.300
- ALLOGRAFT_REJECTION+0.280
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- WNT_BETA_CATENIN_SIGNALING-0.290
- KRAS_SIGNALING_DN-0.210
- COAGULATION-0.190
- MYOGENESIS-0.170
- APICAL_JUNCTION-0.160
- NOTCH_SIGNALING-0.140
- P53_PATHWAY-0.140
- MYC_TARGETS_V2-0.110
- HYPOXIA-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f9c74189-6bdc-49b9-b984-917ffe2b097d | — | — | 0.834 |
| 2 | R427 | — | — | 0.808 |
| 3 | TCGA-BH-A202-01A-11R-A14M-07 | — | C | 0.806 |
| 4 | SRR1797278 | — | cohortSC | 0.804 |
| 5 | SRR6013490 | — | cohortA4 | 0.796 |
| 6 | BS_2EN3X6HB | high-grade glioma | — | 0.794 |
| 7 | TCGA-AR-A0TQ-01A-11R-A084-07 | — | B | 0.793 |
| 8 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.786 |
| 9 | TCGA-C8-A275-01A-21R-A16F-07 | — | C | 0.784 |
| 10 | MNG615 | — | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.540 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |